Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based inhibitor design.

S P Craig1, A E Eakin

  • 1Laboratory of Molecular Parasitology & Drug Design, University of North Carolina School of Pharmacy, Chapel Hill 27599-7360, USA.

Vitamins and Hormones
|February 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.

Antimicrobial agents and chemotherapy·2019
Same author

A Nd(3+)-doped cw fiber laser using all-fiber reflectors.

Applied optics·2010
Same author

Cascade Raman soliton fiber ring laser.

Optics letters·2009
Same author

Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase.

International journal of cancer·2001
Same author

Investigation of the functional role of active site loop II in a hypoxanthine phosphoribosyltransferase.

Biochimica et biophysica acta·2001
Same author

Induction of Tmolt4 leukemia cell death by 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2-4-diones: specificity for type II inosine 5'-monophasphate dehydrogenase.

The Journal of pharmacology and experimental therapeutics·2001
Same journal

Bilateral macronodular and micronodular hyperplasia: Biochemical, radiological and genetic diagnosis.

Vitamins and hormones·2026
Same journal

ACTH independent Cushing's syndrome: Diagnosis and etiology.

Vitamins and hormones·2026
Same journal

Biochemical diagnosis of hypercortisolism: When and how?

Vitamins and hormones·2026
Same journal

New tools for the diagnosis of hypercortisolism.

Vitamins and hormones·2026
Same journal

Cardiometabolic comorbidities in overt Cushing's syndrome.

Vitamins and hormones·2026
Same journal

Molecular profile of Cushing's syndrome.

Vitamins and hormones·2026
See all related articles

Future drug discovery will increasingly use detailed molecular target information, moving beyond random screening methods. This approach enhances efficiency in developing novel chemotherapeutic agents by leveraging structural data.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Computational Biology

Background:

  • Enzyme structure-based approaches have reduced time and costs in discovering chemotherapeutic agents.
  • Current methods still rely on random processes like combinatorial chemistry and high-throughput screening, limiting efficiency.
  • Improved use of structural information is key to further enhancing drug discovery efficiency.

Purpose of the Study:

  • To explore how future drug discovery can better utilize structural information of molecular targets.
  • To highlight the shift from random methodologies towards structure-guided design in drug development.
  • To discuss emerging factors influencing the design of novel chemotherapeutic agents.

Main Methods:

  • Leveraging high-resolution three-dimensional enzyme structures and conformations for inhibitor design.

Related Experiment Videos

  • Investigating the role of water molecules as potential inhibitors of enzyme binding.
  • Employing new computational algorithms to efficiently identify flexible inhibitors from chemical databases.
  • Utilizing molecular genetics tools alongside enzyme structures to address drug resistance.

    • Main Results:

    • High-resolution enzyme structures provide valuable data for inhibitor design.
    • Understanding water's role in enzyme binding is becoming crucial.
    • Computational algorithms enhance the identification of potential drug candidates.
    • Molecular genetics and enzyme structures are vital for combating drug resistance.

    Conclusions:

    • Future drug discovery will increasingly depend on detailed molecular target information.
    • A paradigm shift is occurring from random screening towards structure-based and rational drug design.
    • Integrating structural biology, computational methods, and molecular genetics will accelerate the development of effective chemotherapeutic agents.